Publications by authors named "R E Willard"
Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFArticle Synopsis
- Estrogen receptor (ER) alpha is a key factor in ER+/HER2- breast cancer, and combining current therapies with new drugs is essential due to resistance issues like ESR1 mutations.
- Vepdegestrant (ARV-471) is a new drug that efficiently degrades both wild-type and mutant ER, showing significant tumor growth inhibition in various breast cancer models, outperforming the standard treatment fulvestrant.
- The study suggests that vepdegestrant could be a more effective treatment option for patients with ER+/HER2- breast cancer, especially when combined with other therapies like CDK4/6, mTOR, or PI3K inhibitors.
Hybrid coronary revascularization (HCR) combines a minimally invasive surgical approach with percutaneous coronary intervention (PCI) for the treatment of multivessel coronary artery disease. Despite decades of use, widespread acceptance has been limited. In this review, we conduct a comparative assessment of HCR in relation to traditional coronary artery bypass graft surgery and multivessel PCI.
View Article and Find Full Text PDFBackground: Noninvasive prenatal testing (NIPT) designed to screen for fetal genetic conditions, is increasingly being implemented as a part of routine prenatal care screening in the United States (US). However, these advances in reproductive genetic technology necessitate empirical research on the ethical and social implications of NIPT among populations underrepresented in genetic research, particularly Black women with sickle cell disease (SCD).
Methods: Forty ( = 40) semi-structured interviews were conducted virtually with Black women in the US (19 participants with SCD; 21 participants without SCD) from June 2021 to January 2022.
Advances in reproductive health technologies such as noninvasive prenatal testing (NIPT) are changing the landscape of prenatal care and maternal health. NIPT, made clinically available in the United States (US) in 2011, is a screening test that utilizes cell-free DNA (cfDNA) to detect for aneuploidies and genetic characteristics in fetal DNA. In September 2020, the American College of Obstetricians and Gynecologists (ACOG) recommended NIPT for all pregnant patients regardless of age or risk factors.
View Article and Find Full Text PDF